Article

Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease.

Laboratory for Neurobiology and Gene Therapy, Molecular Medicine, K.U. Leuven, Kapucijnenvoer 33 VCTB+5, B-3000 Leuven, Flanders, Belgium.
Molecular Therapy (Impact Factor: 6.43). 12/2006; 14(5):716-23. DOI: 10.1016/j.ymthe.2006.06.009
Source: PubMed

ABSTRACT Loss-of-function mutations in the PARK2 gene are the major cause of early onset familial Parkinson's disease. The gene product, parkin, is an E3 ligase of the ubiquitin-proteasome pathway involved in protein degradation. Dopaminergic neuron loss may result from the toxic accumulation of parkin substrates, suggesting a key role for parkin in dopaminergic neuron survival. In this study, we have investigated the neuroprotective capacity of parkin in the 6-OHDA rat model for Parkinson's disease. 6-OHDA induces the generation of reactive oxygen species leading to the degeneration of catecholaminergic neurons, but may also impair proteasome activity. Lentiviral vectors encoding human wild-type parkin or green fluorescent protein were stereotactically injected into the substantia nigra 2 weeks prior to a striatal 6-OHDA lesion. Histological analysis 1 and 3 weeks after lesioning showed a significant preservation of dopaminergic cell bodies and nerve terminals. Moreover, lesioned rats overexpressing parkin displayed a corresponding behavioral improvement as measured by the amphetamine-induced rotation test and the cylinder test. The improved performance in the amphetamine-induced rotation test lasted until 20 weeks after lesioning. Our results demonstrate that parkin acts as a potent neuroprotective agent in vivo against 6-OHDA toxic insults. These data support the therapeutic potential of parkin for the treatment of not only familial but also sporadic Parkinson's disease.

Full-text

Available from: Rik Gijsbers, Jun 14, 2015
0 Followers
 · 
108 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Methamphetamine (METH) is a sympathomimetic amine that belongs to phenethylamine and amphetamine class of psychoactive drugs, which are widely abused for their stimulant, euphoric, empathogenic, and hallucinogenic properties. Many of these effects result from acute increases in dopamine and serotonin neurotransmission. Subsequent to these acute effects, METH produces persistent damage to dopamine and serotonin release in nerve terminals, gliosis, and apoptosis. This review summarized the numerous interdependent mechanisms including excessive dopamine, ubiquitin-proteasome system dysfunction, protein nitration, endoplasmic reticulum stress, p53 expression, inflammatory molecular, D3 receptor, microtubule deacetylation, and HIV-1 Tat protein that have been demonstrated to contribute to this damage. In addition, the feasible therapeutic strategies according to recent studies were also summarized ranging from drug and protein to gene level.
    Behavioural neurology 01/2015; 2015:1-11. DOI:10.1155/2015/103969 · 1.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In dieser Arbeit wurde ein Pink1 Knockout Mausmodell für die Parkinson’sche Krankheit generiert und analysiert. Die Tiere sind lebensfähig und fruchtbar. Die Abwesenheit von funktionsfähigem Pink1 hat keinen Einfluss auf die Menge an striatalem Dopamin, die Anzahl der nigralen dopaminergen Neuronen und die mitochondriale Morphologie, aber die Tiere zeigen eine Beeinträchtigung der Complex I-Aktivität und eine leichte Erhöhung an cortikalem Serotonin. Weiterhin wurden Störungen der kognitiven und olfaktorischen Funktion beobachtet, welche diese Mauslinie als vielversprechendes Modell charakterisieren, um frühe nicht-motorische Symptome der Parkinson’schen Krankheit zu untersuchen.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by loss of neurons in the substantia nigra that project to the striatum and release dopamine. The cause of PD remains uncertain, however, evidence implicates mitochondrial dysfunction and oxidative stress. Although most cases of PD are sporadic, 5-10% of cases are caused by inherited mutations. Loss-of-function mutations in Parkin and DJ-1 were the first to be linked to recessively inherited Parkinsonism. Surprisingly, mice bearing similar loss-of-function mutations in Parkin and DJ-1 do not show age-dependent loss of nigral dopaminergic neurons or depletion of dopamine in the striatum. Although the normal cellular functions of Parkin and DJ-1 are not fully understood, we hypothesized that loss-of-function mutations in Parkin and DJ-1 render cells more sensitive to mitochondrial dysfunction and oxidative stress. To test this hypothesis, we crossed mice deficient for Parkin and DJ-1 with mice deficient for the mitochondrial antioxidant protein Mn-superoxide dismutase (SOD2) or the cytosolic antioxidant protein Cu-Zn-superoxide dismutase (SOD1). Aged Parkin (-/-) DJ-1 (-/-) and Mn-superoxide dismutase triple deficient mice have enhanced performance on the rotorod behavior test. Cu/Zn-superoxide dismutase triple deficient mice have elevated levels of dopamine in the striatum in the absence of nigral cell loss. Our studies demonstrate that on a Parkin/DJ-1 null background, mice that are also deficient for major antioxidant proteins do not have progressive loss of dopaminergic neurons but have behavioral and striatal dopamine abnormalities.
    PLoS ONE 12/2013; 8(12):e84894. DOI:10.1371/journal.pone.0084894 · 3.53 Impact Factor